Vitamin K2 deficiency
Conditions
Interventions
After meeting the inclusion criteria, 3x four intervention days (for each MK-7
product four visits) will be planned during a period of 9 weeks. On the first
intervention day, the first blood sample
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Healthy men and women, aged between 20 and 40 years * Normal body weight and height (18.5 kg/m2
Exclusion criteria
Exclusion criteria: * Abuse of drugs and/or alcohol * Use of vitamin supplements containing vitamin K * Soy allergy * Pregnancy * (a history of) metabolic or gastrointestinal diseases including hepatic disorders * Chronic degenerative and/or inflammatory diseases, e.g. diabetes mellitus, renal failure * Use of oral anticoagulants * Corticoid treatment * Subjects with anaemia or subjects who recently donated blood or plasma * Systemic treatment or topical treatment likely to interfere with coagulation metabolism (salicylates, antibiotics) * Chronic degenerative and/or inflammatory diseases * Use of oral anticoagulants * Corticoid treatment * Systemic treatment or topical treatment likely to interfere with evaluation of the study parameters
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Circulating MK-7 levels will be measured at the various points in time: at baseline (before sampling), and 2, 4, 6, 8, 24, 48 and 96 hours after MK-7 supplementation to determine the MK-7 absorption profiles. | — |
Secondary
| Measure | Time frame |
|---|---|
| NVT | — |
Countries
Netherlands
Outcome results
None listed